Central and carboxy-terminal regions of human p53 protein are essential for interaction and complex formation with PARP-1

Journal of Cellular Biochemistry

Volumn 89, Issue 2, 2003, Pages 220-232

  Wȩsierska Ga̧dek, Józefa ^a   Wojciechowski, Jacek ^a   Schmid, Gerald ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KTB Tumorforschungs GmbH   (Germany)

Author keywords

NES masking; p53 export; p53 nucleocytoplasmic shuttling; p53 tetramerization

Indexed keywords

LEPTOMYCIN B; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE) POLYMERASE 1; PROTEIN P53; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CARBOXY TERMINAL SEQUENCE; CELL LYSATE; CONTROLLED STUDY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INSECT CELL; MOUSE; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

ANIMALS; CELLS, CULTURED; CLONING, MOLECULAR; DNA PRIMERS; HUMANS; MICE; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN BINDING; PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

INSECTA;

EID: 0038034413     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10521     Document Type: Article

References (35)

1. Appella E, Anderson CW. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268:2764-2772.
2. Bargonetti J, Manfredi JJn. 2002. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 14:86-91.
3. Blagosklonny M. 2002. P53: An ubiquitous target of anticancer drugs. Int J Cancer 98:161-166.
4. Budihardjo II, Poirier GG, Kaufmann SH. 1998. Apparent cleavage of poly(ADP-ribose) polymerase in non-apoptotic mouse LTA cells: An artifact of cross-reactive secondary antibody. Mol Cell Biochem 1178:245-249.
5. David-Pfeuty T, Chakrani F, Ory K, Nouvian-Doughe Y. 1996. Cell cycle-dependent regulation of nuclear traffic occurs one subclass of human tumor cells and in untransformed cells. Cell Growth Differ 7:1211-1225.
6. Fritsche M, Haessler C, Brandner G. 1993. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8:307-318.
7. Haupt Y, Maya R, Kazaz A, Oren M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
8. Horky M, Wurzer G, Kotala V, Anton M, Vojtesek, Vacha J, Wȩsierska-Ga̧dek J. 2001. Segregation of nucleolar components coincides with caspase-3 activation in cisplatin-treated HeLa cells. J Cell Sci 114:663-670.
9. Jones SN, Roe AE, Donehower LA, Bradley A. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206-208.
10. Kubbutat MH, Jones SN, Vousden KH. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
11. Kumari SR, Mendoza-Alvarez H, Alvarez-Gonzalez R. 1998. Functional interactions of p53 with poly(ADP-ribose) polymerase (PARP) during apoptosis following DNA damage: Covalent poly(ADP-ribosyl)ation of p53 by exogenous PARP and noncovalent binding of p53 to the M(r) 85,000 proteolytic fragment. Cancer Res 58:5075-5078.
12. Maltzman W, Czyzyk L. 1984. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4:1689-1694.
13. Mao L, Merlo A, Bed G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D. 1995. A novel p16INK4A transcript. Cancer Res 55:2995-2997.
14. Montes de Oca Luna R, Wagner DS, Lozano G. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206.
15. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. 1989. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63:4417-4421.
16. Oliner JD, Pientenpol JA, Thiagalingman S, Gyuris J, Kinzler KW, Vogelstein B. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857-860.
17. Pomerantz J, Schreiber-Agus N. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
18. Quelle DE, Zindy F, Ashmun R, Sherr CJ. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000.
19. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
20. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
21. Shah GM, Shah RG, Poirier GG. 1996. Different cleavage pattern for poly(ADP-ribose) polymerase during necrosis and apoptosis in HL-60 cells. Biochem Biophys Res Commun 229:838-844.
22. Shaulsky G, Goldfinger N, Tosky MS, Levine AJ, Rotter V. 1991. Nuclear localization is essential for the activity of p53 protein. Oncogene 6:2055-2065.
23. Simbulan-Rosenthal CM, Rosenthal DS, Iyer S, Boulares AH, Smulson ME. 1998. Transient poly(ADP-ribosyl) ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis. J Biol Chem 273:13703-13712.
24. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM. 1999. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking. EMBO J 18:1660-1672.
25. Vaziri H, West MD, Allsopp RC, Davison TS, Wu YS, Arrowsmith CH, Poirier GG, Benchimol S. 1998. ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J 17:6018-6033.
26. Wȩsierska-Ga̧dek J, Schmid G. 2000. Overexpressed poly(ADP-ribose) polymerase delays the release of rat cells from p53-mediated G(1) checkpoint. J Cell Biochem 80:85-103.
27. Wȩsierska-Ga̧dek J, Schmid G. 2001. Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein. Cell Mol Biol Lett 6:117-140.
28. Wȩsierska-Ga̧dek J, Bugajska-Schretter A, Cerni C. 1996a. ADP-ribosylation of p53 tumor suppressor protein: Mutant but not wild-type p53 is modified. J Cell Biochem 62:90-101.
29. Wȩsierska-Ga̧dek J, Hohenauer H, Hitchman E, Penner E. 1996b. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology 110:840-847.
30. Wȩsierska-Ga̧dek J, Schmid G, Cerni C. 1996c. ADP-ribosylation of wild-type p53 in vitro: Binding of p53 protein to specific p53 consensus sequence prevents its modification. Biochem Biophys Res Commun 224:96-102.
31. Wȩsierska-Ga̧dek J, Wang ZQ, Schmid G. 1999. Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP-deficient mouse fibroblasts. Cancer Res 59:28-34.
32. Wȩsierska-Ga̧dek J, Bohrn E, Herceg Z, Wang ZQ, Wurzer G. 2000. Differential susceptibility of normal and PARP knock-out mouse fibroblasts to proteasome inhibitors. J Cell Biochem 78:681-696.
33. Wȩsierska-Ga̧dek J, Schloffer D, Kotala V, Horky M. 2002. Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy. Int J Cancer 101:128-136.
34. Whitacre CM, Hashimoto H, Tsai ML, Chatterjee S, Berger SJ, Berger NA. 1995. Involvement of NAD-poly(ADP-ribose) metabolism in p53 regulation and its consequences. Cancer Res 55:3697-3701.
35. Wurzer G, Herceg Z, Wȩsierska-Ga̧dek J. 2000. Increased resistance to anticancer therapy of mouse cells lacking the poly (ADP-ribose) polymerase attributable to upregulation of the multidrug resistance gene product P-glycoprotein. Cancer Res 60:4238-4244.